Introduction
============

*Salmonella* infection is a major global public health problem, which has caused food-borne illnesses in many countries. Data from the Foodborne Diseases Active Surveillance Network (Foodnet) report showed that *Salmonella* has become a leading cause of death as a food-borne bacterial pathogens in the United States ([@B2]). Among the more than 2500 serotypes of *Salmonella* ([@B29]), *S.* Typhimurium is one of the predominant serotypes in many developed and developing countries, and the global outbreak of food-borne diseases due to infection by *S*. Typhimurium is impressive. *S.* Typhimurium infection was very common in the United States; for example, *S.* Typhimurium enteritis had been diagnosed in 600 persons in 44 states due to peanut butter contamination in 2008 ([@B22]). *S.* Typhimurium infection has also been often reported in China and was found to be the second most prevalent serotype ([@B30]).

Antimicrobial treatment is needed for infants, the elderly, and immunocompromised individuals with *Salmonella* infection. Fluoroquinolones and cephalosporins are the primary choice for clinical treatment ([@B13]). In addition, azithromycin has gained the approval of the Food and Drug Administration (FDA) as an additional agent to treat *Salmonella* infections ([@B34]). With the extensive use of such antimicrobials, antimicrobial resistance is increasing at a serious rate in *Salmonella* isolates. In many countries, more and more *Salmonella* strains with MDR (defined as resistance to three or more classes of antimicrobials) have been discovered since the 1990's report of the spread of MDR in *S.* Typhimurium of definitive phage type 104 (DT104) in the world ([@B25]). Relevant monitoring data showed that MDR in the entire *Salmonella* genus has increased from 20 to 30% in the early 1990s to 70% at the beginning of this century ([@B35]). *S.* Typhimurium has also been found to show high rates of resistance to the traditional antimicrobials, and resistance to ciprofloxacin or cephalosporins have been found to have emerged in countries such as France and the United States ([@B37]; [@B38]). A mass of *S.* Typhimurium isolates were also found to be resistant to ciprofloxacin or cephalosporins in many cities of China ([@B9]; [@B16]). In recent years, some cases of azithromycin- resistance in patients with *Salmonella* infection were reported ([@B34]). Surprisingly, two strains have even been reported to be concurrently resistant to ciprofloxacin, cephalosporins, and azithromycin in China ([@B39]).

Shanghai is an economic and financial center located in eastern China and is divided into 16 administrative units with more than 24 million people. In order to better monitor public health issues, the Shanghai Center for Disease Control and Prevention (SCDC) became a member of the World Health Organization Global Food-borne Infections Network (WHO-GFN) in 2005 ([@B42]). In this study, we aimed to analyze the antimicrobial resistance profiles of *S.* Typhimurium in Shanghai from 2011 to 2014 and tried to elucidate the molecular mechanisms underlying the emergence of MDR in these isolates. Our findings highlight the importance of increasing surveillance on these isolates with MDR, which will help provide appropriate clinical antimicrobial treatment for patients with *S.* Typhimurium infection.

Materials and Methods {#s1}
=====================

Specimen Collection and Isolate Identification
----------------------------------------------

Fresh stool samples from clinically suspected patients who had diarrhea were collected from 24 sentinel hospitals and eight regional SCDC diagnostic laboratories in Shanghai as described previously ([@B42]). The stool samples were then enriched in Selenite Brilliant Green broth (CHROMagar, China) for 16--22 h at 37°C. The enriched samples were then cultivated on *Salmonella-Shigella* (SS) agar or xylose lylose deoxycholate agar (XLD; CHROMagar, China) and incubated for 18--24 h at 37°C. Presumptive colonies were screened by testing in triple-sugar-iron agar, motility indole urea agar, [L]{.smallcaps}-lysine decarboxylase, and [L]{.smallcaps}-galactosidase (*o*-nitrophenyl-[L]{.smallcaps}-[D]{.smallcaps}-galactopyranoside; ONPG). One presumptive colony from each sample was stored in semisolid agar and sent to our laboratory for further confirmation. API 20E test strips (bioMerieux Vitek, Marcy-l'Etoile, France) were used to confirm the identity of the isolates. All the isolates were then serotyped by slide agglutination with commercial antiserum (S&A Reagents Laboratory, Thailand) according to the Kauffmann-White scheme ([@B40]). This study was approved by Institute of Disease Control and Prevention, Academy of Military Medical Sciences (Beijing, China) and the informed consent was obtained from the subjects involved in this study.

Antimicrobial Susceptibility Testing
------------------------------------

The minimum inhibitory concentrations (MICs) for 14 antimicrobial agents including cefoxitin (FOX), ceftriaxone (CRO), ceftiofur (XNL), azithromycin (AZI), chloramphenicol (CHL), tetracycline (TET), ciprofloxacin (CIP), gentamicin (GEN), nalidixic acid (NAL), sulfisoxazole (FIS), ampicillin (AMP), streptomycin (STR), amoxicillin/clavulanic acid at a 2:1 ratio (AUG2), and trimethoprim/sulfamethoxazole (SXT) were evaluated by broth microdilution using the Sensititre plate CMV3AGNF (Sensititre, Thermo Fisher Scientific, USA) according to the recommendations of the Clinical and Laboratory Standards Institute (CLSI) ([@B8]). An *Escherichia coli* ATCC 25922 strain was used for quality control.

PCR Amplification and DNA Sequencing
------------------------------------

All the cephalosporin-resistant isolates were analyzed using PCR assays for the presence of extended-spectrum β-lactamase (ESBL) genes such as *bla*~CTX-M~ groups, *bla*~OXA~, *bla*~TEM~, *bla*~SHV~, and *bla*~CMY~ ([@B14]; [@B37]; [@B10]). PCR amplification of quinolone resistance-determining regions (QRDRs) of *gyrA, gyrB, parC*, and *parE* ([@B12]) and plasmid-mediated quinolone resistance (PMQR) determinants \[*qnrA, qnrB, qnrD, qnrS*, and *aac(6′)-Ib-cr*\] ([@B27]; [@B10]) were performed on the ciprofloxacin-resistant or intermediate resistant isolates. All azithromycin-resistant isolates were subjected to PCR to detect macrolide-resistance genes including *mphA, mphB, ermA, ermB, ereA, mefA*, and *msrA* ([@B28]). The primers used for the above mentioned PCR amplifications are shown in **Table [1](#T1){ref-type="table"}**. All the PCR products were sequenced by the Beijing Genomics Institute (BGI). Sequences data were then analyzed by DNAstar (DNAstar Inc., Madison, WI, USA) and the sequences were compared with reference sequences from NCBI GenBank.

###### 

Primers for the PCR detection of antimicrobal-resistance determinants.

  Target                            Primer sequence (5′--3′)      Amplicon size (bp)   Reference
  --------------------------------- ----------------------------- -------------------- ------------
  **β-Lactamases**                                                                     
  *bla*~CTX-M-1~ group              F:GGTTAAAAAATCACTGCGTC        873                  [@B10]
                                    R:TTACAAACCGTCGGTGACGA                             
  *bla*~CTX-M-9~ group              F:AGAGTGCAACGGATGATG          868                  [@B10]
                                    R:CCAGTTACAGCCCTTCGG                               
  *bla*~CTX-M-2/8/25~ group         F:ACCGAGCCSACGCTCAA           221                  [@B10]
                                    R:CCGCTGCCGGTTTTATC                                
  *bla*~OXA-1~ group                F:ATGAAAAACACAATACATATC       830                  [@B37]
                                    R:AATTTAGTGTGTTTAGAATGG                            
  *bla*~TEM~                        F:ATAAAATTCTTGAAGACGAAA       1080                 [@B37]
                                    R:GACAGTTACCAATGCTTAATC                            
  *bla*~SHV~                        F:TTATCTCCCTGTTAGCCACC        795                  [@B37]
                                    R:GATTTGCTGATTTCGCTCGG                             
  *bla*~CMY~                        F:GTGGTGGATGCCAGCATCC         915                  [@B14]
                                    R:GGTCGAGCCGGTCTTGTTGAA                            
  **QRDR of Topoisomerase genes**                                                      
  *gyrA*                            F: TGGGCAATGACTGGAACA         431                  This study
                                    R: GGTTGTGCGGCGGGATA                               
  *gyrB*                            F: ATGAGCGATATGGCAGAGCG       309                  [@B10]
                                    R:GCTGTGATAACGCAGTTTGTCCGGG                        
  *parC*                            F:ATGAGCGATATGGCAGAGCG        413                  [@B12]
                                    R:TGACCGAGTTCGCTTAACAG                             
  *parE*                            F:ATGCGTGCGGCTAAAAAAGTG       290                  [@B10]
                                    R:TCGTCGCTGTCAGGATCGATAC                           
  **PMQR**                                                                             
  *qnrA*                            F:ATTTCTCACGCCAGGATTTG        516                  [@B10]
                                    R:GATCGGCAAAGGTTAGGTCA                             
  *qnrB*                            F:GATCGTGAAAGCCAGAAAGG        469                  [@B10]
                                    R:ACGATGCCTGGTAGTTGTCC                             
  *qnrD*                            F:CGAGATCAATTTACGGGGAATA      656                  [@B10]
                                    R:AACAAGCTGAAGCGCCTG                               
  *qnrS*                            F:ACGACATTCGTCAACTGCAA        417                  [@B10]
                                    R:TAAATTGGCACCCTGTAGGC                             
  *aac(6′)-Ib-cr*                   F:TTGCGATGCTCTATGAGTGGCTA     482                  [@B27]
                                    R:CTCGAATGCCTGGCGTGTTT                             
  **Macrolide-resistance Genes**                                                       
  *mphA*                            F:GTGAGGAGGAGCTTCGCGAG        403                  [@B28]
                                    R:TGCCGCAGGACTCGGAGGTC                             
  *mphB*                            F:GATATTAAACAAGTAATCAGAATAG   494                  [@B28]
                                    R:GCTCTTACTGCATCCATACG                             
  *ermA*                            F:TCTAAAAAGCATGTAAAAGAAA      533                  [@B28]
                                    R:CGATACTTTTTGTAGTCCTTC                            
  *ermB*                            F:GAAAAAGTACTCAACCAAATA       693                  [@B28]
                                    R:AATTTAAGTACCGTTACT                               
  *ereA*                            F:GCCGGTGCTCATGAACTTGAG       420                  [@B28]
                                    R:CGACTCTATTCGATCAGAGGC                            
  *mefA*                            F:AGTATCATTAATCACTAGTGC       345                  [@B28]
                                    R:TTCTTCTGGTACTAAAAGTGG                            
  *msrA*                            F:GCACTTATTGGGGGTAATGG        384                  [@B28]
                                    R:GTCTATAAGTGCTCTATCGTG                            

Statistical Analysis
--------------------

Chi-squared test was used for data analysis using SPSS software (SPSS Inc., Chicago, IL, USA; version 17.0); a *P-*value \< 0.05 was considered to indicate statistical significance.

Results
=======

*S.* Typhimurium Isolates from Human Patients in Shanghai, China, from 2011 to 2014
-----------------------------------------------------------------------------------

Between January 2011 and December 2014, 559 *S.* Typhimurium isolates were cultured from patients with diarrhea in Shanghai, China. The age of the patients ranged from 10 days to 86 years (19 cases unknown) (**Figure [1](#F1){ref-type="fig"}**). Children under 5 years of ages, and especially less than 1-year-old children, were highly susceptible to *S.* Typhimurium infection, which accounted for 49.4% of all the patients (*P* \< 0.05). The ratio of the male to female patients was 1.3:1. Infections occurred mainly in summer and autumn (**Figure [1](#F1){ref-type="fig"}**).

![**Distribution of human *S.* Typhimurium isolates in patients by (A)** age and **(B)** months (2011--2014) in Shanghai, China.](fmicb-08-00510-g001){#F1}

Antimicrobial Susceptibility Testing
------------------------------------

Among the 559 isolates, only 26 (4.7%) were susceptible to all 14 antimicrobials. Resistance to tetracycline was the most common (83.7%), followed by ampicillin (80.1%), nalidixic acid (79.2%), sulfisoxazole (77.1%), chloramphenicol (54.9%), streptomycin (53.7%), trimethoprim/sulfamethoxazole (47.4%), gentamicin (37%), and amoxicillin/clavulanic acid (7.9%) (**Table [2](#T2){ref-type="table"}**). In addition, resistance to ceftiofur, ceftriaxone, and cefoxitin was found in 20, 20, and 5% of isolates, respectively. Notably, 3.6% (20/599) of the isolates displayed resistance (MIC ≥ 4 μg/mL) to ciprofloxacin, and 9.1% (51/599) exhibited intermediate resistance to ciprofloxacin (MICs = 2 μg/mL). More importantly, 22 of the isolates showed co-resistance to cephalosporins. Moreover, 31 (5.5%) isolates were showed resistance to azithromycin, and 6 of them were co-resistant to cephalosporins and ciprofloxacin.

###### 

Antimicrobial resistance of *S.* Typhimurium isolates in Shanghai from 2011 to 2014.

                                  *N* (%) of resistant isolates                                          
  ------------------------------- ------------------------------- ------------ ------------ ------------ ------------
  **Pan-susceptible**             4 (5.2)                         8 (5.2)      4 (2.4)      10 (6.3)     26 (4.7)
  Nalidixic Acid                  67 (87)                         107 (60)     145 (86.8)   124 (77.5)   443 (79.2)
  Ciprofloxacin                   7 (9.1)                         4 (2.6)      6 (3.6)      3 (1.9)      20 (3.6)
  Ampicillin                      54 (70.1)                       124 (80)     150 (89.8)   120 (75)     448 (80.1)
  Ceftiofur                       23 (29.9)                       37 (23.9)    30 (18)      22 (13.8)    112 (20)
  Cefoxitin                       8 (10.4)                        17 (10.3)    1 (0.6)      2 (3.8)      28 (5)
  Ceftriaxone                     23 (29.9)                       37 (23.9)    30 (18)      22 (13.8)    112 (20)
  Tetracycline                    58 (75.3)                       124 (80)     156 (93.4)   130 (81.3)   468 (83.7)
  Streptomycin                    33 (42.9)                       74 (47.7)    97 (58.1)    96 (60)      300 (53.7)
  Gentamicin                      29 (37.7)                       62 (40)      81 (48.5)    35 (21.9)    207 (37)
  Chloramphenicol                 31 (40.3)                       86 (55.5)    124 (74.3)   66 (41.3)    307 (54.9)
  Azithromycin                    1 (1.3)                         13 (8.4)     4 (2.4)      13 (8.1)     31 (5.5)
  Sulfisoxazole                   27 (35.1)                       126 (81.3)   156 (93.4)   122 (76.3)   431 (77.1)
  trimethoprim/sulfamethoxazole   31 (40.3)                       76 (49)      97 (58.1)    61 (38.1)    265 (47.4)
  amox-icillin/clavulanic acid    9 (11.7)                        20 (12.9)    5 (3)        10 (6.3)     44 (7.9)
  **MDR pattern**                                                                                        
  ≥3 antimicrobials               56 (72.7)                       130 (83.9)   159 (95.2)   128 (80)     473 (84.6)
  ≥4 antimicrobials               51 (66.2)                       121 (78.1)   147 (88)     116 (72.5)   435 (77.8)
  ≥5 antimicrobials               40 (51.9)                       91 (58.7)    125 (74.9)   85 (53.1)    341 (61)
  ≥6 antimicrobials               25 (32.5)                       52 (33.5)    91 (54.5)    47(29.4)     215 (38.5)
  ≥7 antimicrobials               1 (1.3)                         0 (0)        1 (0.6)      4 (2.5)      6 (1.1)
  ACSSuT                          15 (19.5)                       42 (27.1)    66 (39.5)    38 (23.8)    161 (28.8)
  ACSSuT+CIP                      5 (6.5)                         6 (3.9)      18 (10.8)    11 (6.9)     40 (7.2)
  ACSSuT+CEP                      7 (9.1)                         15 (9.7)     8 (4.8)      6 (3.8)      36 (6.4)
  ACSSuT+AZI                      1 (1.3)                         2 (1.3)      1 (0.6)      6 (3.8)      10 (1.8)
  ACSSuT+CIP+CEP                  2 (2.6)                         0 (0)        2 (1.2)      2 (1.3)      6 (1.1)
  ACSSuT+CIP+CEP+AZI              1 (0.2)                         0 (0)        0 (0)        0 (0)        1 (0.2)

CIP, Ciprofloxacin; CEP, cephalosporins; AZI, Azithromycin.

Multidrug resistance was observed in 84.6% of the isolates, in which ≥3, ≥4, ≥5, ≥6, and ≥7 classes of antimicrobials were found in 84.6, 77.8, 61, 38.5, and 1.1% of the MDR isolates, respectively. Among the MDR isolates, 161 (28.8%) showed the ACSSuT resistance pattern (defined as resistance to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole, and tetracycline); among them, 40 (7.2%) isolates exhibited reduced susceptibility to ciprofloxacin, 36 (6.4%) were resistant to cephalosporins, and 10 (1.8%) were resistant to azithromycin. It is noteworthy that 6 (1.1%) isolates with ACSSuT resistance pattern were concurrently resistant to ciprofloxacin and cephalosporins, and one of them was also co-resistant to azithromycin (**Table [2](#T2){ref-type="table"}**).

PCR Detection of Antimicrobial Drug Resistance Genes and DNA Sequencing
-----------------------------------------------------------------------

Resistance genes including *bla*~OXA~, *bla*~TEM~, *bla*~SHV~, *bla*~CMY~, *and bla*~CTX-M~ in the 115 cephalosporin-resistance isolates were detected by PCR. PCR screenings revealed that 75 (65.2%), 52 (45.2%), 43 (37.4%), and 3 (2.6%) isolates contained the *bla*~CTX~, *bla*~TEM~, *bla*~OXA~, and *bla*~SHV~ genes, respectively. All the strains were negative for *bla*~CMY~. Fifty-two isolates contained two of the above described genes (*bla*~CTX-M~+*bla*~TEM~*/bla*~CTX-M~+*bla*~OXA~*/bla*~TEM~+*bla*~SHV~), and nine isolates concurrently contained *bla*~CTX-M~, *bla*~TEM~, and *bla*~OXA~. Sequencing of the PCR products revealed that *bla*~TEM-1~, *bla*~OXA-1~, and *bla*~SHV\ -12~ were the main genotypes. *bla*~CTX-M~ included eight subtypes: *bla*~CTX-M-14~, *bla*~CTX-M-15~, *bla*~CTX-M-27~, *bla*~CTX-M-55~, *bla*~CTX-M-65~, *bla*~CTX-M-104~, *bla*~CTX-M-123~, and *bla*~CTX-M-125~, among which *bla*~CTX-M-14~ and *bla*~CTX-M-55~ were the most common subtypes (**Figure [2](#F2){ref-type="fig"}**).

![**The CTX-M proportions of cephalosporin-resistant *S.* Typhimurium isolates.** The digit before ";" indicates the number of isolates that contained *bla*~CTX-M~ genes, and the digit after ";" indicates the percentage of isolates that contained *bla*~CTX-M~ genes.](fmicb-08-00510-g002){#F2}

We identified 71 isolates with decreased susceptibility to ciprofloxacin, and 65 of them contained at least one *gyrA* mutation which mainly occurred at encode 87 (D87Y, D87N, or D87G). Among them, six had double mutations (S83F/D87N or D87G) in the *gyrA* gene and a single mutation (S80R) in the *parC* gene; 1 isolate with four mutations, including two in *gyrA* gene (S83F/D87N) and two in *parC* gene (T57S/S80R); 58 isolates with only one *gyrA* mutation (D87Y or D87N). No point mutations in *gyrB* and *parE* were found. Here, three species of PMQR determinants including *aac(6′)-Ib-cr* (*n* = 50), *qnrB* (*qnrB2, n* = 2; *qnrB4, n* = 4), and *qnrS1* (*n* = 1) were detected. Among the 49 isolates with no mutation or only one mutation in *gyrA* gene, one or two PMQR genes were detected (**Table [3](#T3){ref-type="table"}**).

###### 

Distribution of PMQR genes and mutations in *gyrA, gyrB, parC*, and *parE* genes in *S.* Typhimurium isolates with decreased susceptibility to ciprofloxacin in Shanghai, China.

  QRDR mutation   PMQR   *N*         Total                                     
  --------------- ------ ----------- ------- ------------------------ ---- --- ----
  WT              WT     WT          WT      *qnrS*                   1    0   1
  WT              WT     WT          WT      *aac(6*′*)-Ib-cr*        1    0   1
  WT              WT     WT          WT      *aac(6*′*)-Ib-cr,qnrB*   1    3   4
  D87Y            WT     WT          WT      WT                       15   0   15
  D87Y            WT     WT          WT      *aac(6*′*)-Ib-cr*        20   4   24
  D87N            WT     WT          WT      *aac(6*′*)-Ib-cr*        13   4   17
  D87Y            WT     WT          WT      *aac(6*′*)-Ib-cr,qnrB*   0    2   2
  S83F/D87N       WT     S80R        WT      WT                       0    4   4
  S83F/D87N       WT     S80R        WT      *aac(6*′*)-Ib-cr*        0    1   1
  S83F/D87G       WT     S80R        WT      WT                       0    1   1
  S83F/D87N       WT     T57S/S80R   WT      *aac(6*′*)-Ib-cr*        0    1   1

∗

S

. Typhimurium isolates with intermediate resistance to CIP (MIC = 2 μg/mL);

∗∗

S

. Typhimurium isolates with resistance to CIP (MIC ≥ 4 μg/mL); WT, wild type.

In addition, PCR results showed that 15 out of the 31 azithromycin-resistant isolates (MIC ≥ 128 μg/mL) harbored *mphA* genes, while the other 16 (MIC: 16--64 μg/mL) did not. All the azithromycin-resistant isolates were negative for *mphB, ermA, ermB, ereA, mefA*, and *msrA*.

Notably, among the 22 isolates that concurrently exhibited reduced susceptibility to cephalosporins and ciprofloxacin, 15 contained ESBL and PMQR genes. Two isolates contained four types of antimicrobial-resistance genes: *qnrB*/*aac(6*′*)-Ib-cr*/*bla*~CTX-M~/*bla*~TEM~ (*n* = 1) and *aac(6*′*)-Ib-cr/bla*~OXA~/*bla*~CTX-M~/*bla*~TEM~ (*n* = 1). Nine isolates harbored three types of antimicrobial resistant genes, including *qnrB /aac(6*′*)-Ib-cr/bla*~OXA~ (*n* = 2), *aac(6*′*)-Ib-cr/bla*~OXA~/*bla*~CTX-M~ (*n* = 4), and *aac(6*′*)-Ib-cr*/*bla*~CTX-M~/*bla*~TEM~ (*n* = 3). Four isolates contained two types of antimicrobial-resistant genes: *aac(6*′*)-Ib-cr*/*bla*~TEM~ (*n* = 2) and *aac(6*′*)-Ib-cr*/*bla*~CTX-M~ (*n* = 2). In addition, 2 out of the 15 isolates that were co-resistant to azithromycin concurrently harbored ESBL, PMQR, and *mphA* genes: *aac(6*′*)-Ib-cr*/*bla*~CTX-M~*/bla*~TEM~/*mphA* (**Table [4](#T4){ref-type="table"}**).

###### 

Summary of phenotypes of *S.* Typhimurium isolates showing concurrently decreased susceptibility to ciprofloxacin and cephalosporins and their corresponding resistance genes.

  Strain       MIC (μg/mL)   QRDR mutation   PMQR   ESBL   *mphA*                                                                                            
  ------------ ------------- --------------- ------ ------ -------- ----------- ----------- ------------------------ --------------------------------------- --------
  SHI 1G663    \>32          4               8      4      4        WT          WT          *qnrB/aac(6*′*)-Ib-cr*                                           
  SHI 1G664    \>32          8               \>8    4      2        WT          WT          *qnrB/aac(6*′*)-Ib-cr*   *bla*~OXA~                              
  SHI 1G665    \>32          32              8      4      4        WT          WT          *qnrB/aac(6*′*)-Ib-cr*   *bla*~OXA~                              
  SH11G680     4             \>64            \>8    \>4    2        S83F/D87N   S80R                                 *bla*~OXA~*/bla*~CTX-M-55~              
  SHI 1G993    \>32          16              \>8    \>4    256      S83F/D87N   S80R                                 *bla*~OXA~                              *mphA*
  SH11G1304    2             \>64            \>8    2      4        D87Y        WT          *aac(6*′*)-Ib-cr*        *bla*~OXA~/bla~CTX-M-27~                
  SH11G1306    2             \>64            \>8    2      4        D87Y        WT                                                                           
  SHI 2G734    32            \<0.25          2      2      4        D87Y        WT          *aac(6*′*)-Ib-cr*        *bla*~TEM~                              
  SHI 2G889    32            \<0.25          2      4      8        D87Y        WT          *aac(6*′*)-Ib-cr*        *bla*~OXA~*/bla*~CTX-M-14~*/bla*~TEM~   
  SH12G978     32            \>64            \>8    2      64       WT          WT          *qnrB/aac(6*′*)-Ib-cr*   *bla*~CTX-M-15~*/bla*~TEM~              
  SHI 2G1005   8             \>64            \>8    \>4    64       S83F/D87N   T57S/S80R   *aac(6*′*)-Ib-cr*        *bla*~CTX-M-65~/*bla*~TEM~              
  SHI 3G355    2             \>64            \>8    2      4        D87N        WT          *aac(6*′*)-Ib-cr*        *bla*~TEM~                              
  SHI 3G769    2             \>64            \>8    2      4        D87N        WT          *aac(6*′*)-Ib-cr*        *bla*~CTX-M-14~                         
  SHI 3G938    16            \>64            \>8    2      4        D87N        WT                                   *bla*~OXA~*/bla*~CTX-M-55~              
  SHI 3G939    16            \>64            \>8    2      4        D87N        WT                                   *bla*~OXA~*/bla*~CTX-M-55~              
  SH13G1219    8             \>64            \>8    \>4    128      D87Y        WT          *aac(6*′*)-Ib-cr*        *bla*~CTX-M-15~*/bla*~TEM~              *mphA*
  SHI 3G1825   2             \>64            \>8    \>4    128      D87Y        WT          *aac(6*′*)-Ib-cr*        *bla*~CTX-M-15~*/bla*~TEM~              *mphA*
  SHI 4G287    4             \>64            \>8    2      8        WT          WT          *aac(6*′*)-Ib-cr*        *bla*~OXA~*/bla*~CTX-M-125~             
  SHI 4G294    8             64              \>8    2      8        D87N        WT          *aac(6*′*)-Ib-cr*        *bla*~OXA~*/bla*~CTX-M-125~             
  SHI 4G300    4             64              \>8    2      64       D87N        WT          *aac(6*′*)-Ib-cr*        *bla*~OXA~*/bla*~CTX-M-125~             
  SHI 4G1345   4             \>64            \>8    2      4        D87Y        WT                                   *bla*~OXA~*/bla*~CTX-M-55~*/bla*~TEM~   
  SH14G1601    2             \>64            \>8    2      4        D87N        WT          *aac(6*′*)-Ib-cr*        *bla*~CTX-M-55~                         

FOX, cefoxitin; CRO, ceftriaxone; XNL, ceftiofur; CIP, ciprofloxacin; AZI, azithromycin; WT, wild type.

Discussion
==========

In present study, we found that *S.* Typhimurium isolates in Shanghai, China, exhibited high rates of resistance to traditional antimicrobials, such as tetracycline, ampicillin, nalidixic acid, and sulfisoxazole. Moreover, resistance to cephalosporins, ciprofloxacin and azithromycin were found in 20.6, 3.6, and 5.5% of the isolates, respectively. Contradictory to this result from the current study, the report of the NARMS indicated that the number of cephalosporin-resistant, ciprofloxacin-resistant and azithromycin-resistant isolates was lower than 6, 1, and 1% (2011--2014), respectively ([@B7]). More importantly, 84.6% of the isolates were found to exhibit MDR in our study, which is significantly higher than the percentage observed from the surveillance data during 2005 to 2010 in Shanghai and that indicated in the NARMS report for the same period (*P* \< 0.05) ([@B42]; [@B7]). Notably, in the current study, we found that 22 MDR isolates with decreased susceptibility to ciprofloxacin were co-resistant to cephalosporins. Six of the 22 isolates also showed resistance to azithromycin. This phenomenon has only been reported previously in two clinical *S.* Typhimurium strains in China ([@B39]). If these MDR strains are as prevalent as *S.* Typhimurium DT104 all over the world, it will pose a great threat to global public health. Our findings indicate that it is therefore necessary to continue monitoring the antimicrobial resistance of *S.* Typhimurium isolates to help determine the appropriate antimicrobial therapy for patients with *S.* Typhimurium infection. More importantly, it is necessary to study the mechanisms underlying the antimicrobial resistance in these isolates.

The main mechanisms of quinolone-resistance in *Salmonella* have been attributed to several point mutations in the QRDRs of the *gyrA* and *parC* genes and the PMQR genes ([@B15]; [@B18]). Mutations at different sites contribute to different levels of resistance to ciprofloxacin, and simultaneous mutations in both *gyrA* and *parC* genes produce high levels of ciprofloxacin resistance. Besides, most isolates with decreased susceptibility to ciprofloxacin contain a mutation in *gyrA* or PMQR genes ([@B20]; [@B19]). In the present study, we found that six isolates had double mutations (S83F/D87N or D87G) in the *gyrA* gene and a single mutation (S80R) in the *parC* gene. Additionally, one isolate with four mutations, including two in *gyrA* gene (S83F/D87N) and two in *parC* gene (T57S/S80R). These mutations have been previously reported to be most common in ciprofloxacin-resistant *S.* Typhimurium strains ([@B36]). PMQR was initially identified in *Klebsiella pneumonia* in 1998 ([@B23]), since then, various types of PMQR genes have been detected in *Salmonella* all over the world ([@B5]; [@B6]; [@B18]). Previous studies have shown that the presence of *qnr* genes increase the MICs for ciprofloxacin by 8--16-fold ([@B18]). In addition, the presence of *aac(6′)-Ib-cr* genes can increase the selection of chromosomal mutants that cause ciprofloxacin resistance ([@B33]). In the current study, we also showed that the existence of PMQR genes remarkably enhances the MICs (≥2 μg/mL) of ciprofloxacin in the presence of a single or no point mutation in the *gyrA* gene in *S.* Typhimurium isolates. The emergence of PMQR genes described in this report has also been frequently reported previously in *Salmonella* isolates in other parts of China ([@B21]; [@B16]; [@B39]), which suggests that the PMQR genes have been prevalent in China.

Since the discovery of *bla*~CTX-M~ genes in Japan, Europe, and South America in the 1980s ([@B24]; [@B4], [@B3]), they have quickly replaced *bla*~TEM~ and *bla*~SHV~ as the major ESBL ([@B11]). In the present study, of the 115 cephalosporin-resistant isolates, 62.5% harbored *bla*~CTX-M~ genes, in which *bla*~CTX-M-55~ was the most common gene, followed by *bla*~CTX-M-14~. This phenomenon proved that the *bla*~CTX-M-1~ and *bla*~CTX-M-9~ groups are popular types in *S.* Typhimurium isolates in Shanghai. Besides, the subtypes of *bla*~CTX-M-123~ and *bla*~CTX-M-125~ have also been identified in *E. coli* ([@B31]), but have not been found in *Salmonella*. To the best of our knowledge, this study is the first to report *bla*~CTX-M-123~ and *bla*~CTX-M-125~ in *S.* Typhimurium. In addition, 52 (45.2%), 43 (37.4%), and 3 (2.6%) isolates were found to contain the *bla*~TEM-1~, *bla*~OXA-1~, and *bla*~SHV\ -12~ genes, respectively. Because the ESBL genes are usually located on the antimicrobial-resistance plasmid of the bacteria, they can be easily disseminated between different species of bacteria with the transfer of the drug-resistance plasmid ([@B1]).

As the number of cephalosporin-resistant and ciprofloxacin-resistant *Salmonella* strains gradually increased, an alternative antimicrobial class was needed to manage *Salmonella* infections. Azithromycin showed excellent ability to accumulating at high intracellular concentrations, and it achieved intracellular concentrations of 50 to 100 times greater than the serum levels ([@B26]). Therefore, azithromycin was recommended for the treatment of invasive *Salmonella* infections by the FAD ([@B34]). However, in the present study, 31(5.5%) isolates were found to be resistant to azithromycin. Previously, *Salmonella* strains resistant to azithromycin have also been found in other countries ([@B34]; [@B17]). The plasmid-borne *mphA* gene was reported as one of the reasons of azithromycin-resistance ([@B13]). In the present study as well, 15 high-level azithromycin-resistant isolates (MIC ≥ 128 μg/mL) harbored the *mphA* gene, while other 16 (MIC: 16--64 μg/mL) did not. All azithromycin-resistant isolates were negative for *mphB, ermA, ermB, ereA, mefA*, and *msrA*. These results indicate that the *mphA* gene may mediate a high level of resistance to azithromycin in *Salmonella*, as described previously in *Shigella* in China ([@B41]). In addition, azithromycin resistance may arise from other possible mechanisms, such as mutations in the *rlpD* and *rlpV* genes ([@B32]). At present, few studies have been focused on investigating azithromycin resistance mechanisms in *Salmonella*. The findings of the present study and those of other previous studies emphasize the need for investigating the further mechanisms underlying azithromycin resistance in *Salmonella* isolates.

Antimicrobial-resistance genes are usually located on plasmids and therefore can be easily disseminated; for example the ESBL genes often coexist with the genes encoding resistance to other antimicrobial agents in plasmids, which can easily lead to a MDR phenotype in ESBL-producing bacteria ([@B16]). In this study, we found that 15 isolates showed both ESBL and PMQR genes, in which concurrently displayed decreased susceptibility to cephalosporins and ciprofloxacin. Besides, 2 of the 15 isolates co-contained *mphA* genes, which were resistant to azithromycin.

Conclusion
==========

In this study, we reported the common occurrence of MDR in *S.* Typhimurium isolates in Shanghai, China. We found that resistance to ciprofloxacin, cephalosporins, and azithromycin was most prevalent among the isolates. Among the MDR isolates, we found various transferrable antimicrobial-resistance genes, which included ESBL, PMQR and *mphA* genes, and some isolates even contained at least two types of these genes. The dissemination of these genes poses a huge threat to the control of *S.* Typhimurium infection in the world. Our findings indicate that it is imperative to continue monitoring the prevalence of the above-mentioned three types of antimicrobial resistance and their resistant genes in *S.* Typhimurium isolates. Future studies should be focused on identifying ways to prevent the dissemination of these antimicrobial-resistance genes.
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